Question · Q4 2025
Jeffrey Grampp asked about the contribution of the $150 million in large orders booked in 2025 to the 2026 guidance, or if most of it is expected in 2027 and beyond. He followed up by asking for more context on SMRs being a bigger factor in 2026 growth (as noted on slide 23) and their materiality to Mirion's growth story in the coming years.
Answer
Brian Schopfer, CFO and Medical Group President, clarified that while some of the large orders booked in late Q4 2025 contribute to 2026, the first year of these larger contracts tends to be the lightest, with ramping typically occurring after 18 months into years two, three, and four. Thomas Logan, CEO and Chairman, noted the difficulty in contextualizing SMRs due to the sheer volume of global projects, but highlighted contractual relationships with over 20 SMR developers and extraordinary order growth in 2025. Brian Schopfer added that SMRs were sub-1.5% of total revenue in 2025, growing to sub-3% in 2026, indicating growth but not yet meaningful in the grand scheme.
Ask follow-up questions
Fintool can predict
MIR's earnings beat/miss a week before the call
